ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Valuation Check As New Share Buy-Back Targets 5% Of Share Capital
Neuren Pharmaceuticals (ASX:NEU) has announced a new share buy-back program, authorising repurchases of up to 6,350,631 shares, or 5% of its issued capital, through to March 2027.
See our latest analysis for Neuren Pharmaceuticals.
The buy-back comes after a sharp 30 day share price return of around a 30% decline and a 90 day share price return of about a 29% decline, even though the 1 year and multi year total shareholder returns remain positive and very strong. This suggests recent selling...